Search

Lawsonia inermis leaf

Lawsonia inermis leaf is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

DT-DEC01

DT-DEC01 is a novel Dystrophin Expressing Chimeric (DEC) cell therapy being investigated by Dystrogen Therapeutics Corporation.

Trodusquemine

It has demonstrated the ability to stimulate regeneration of heart and multiple other tissues in animal models [A176600]. … Trodusquemine, a spermine metabolite of cholesterol, is a naturally occurring aminosterol that inhibits protein tyrosine phosphatase 1B.

2-Methoxyestradiol

2-Methoxyestradiol (2ME2) is a drug that prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis).

Brolucizumab

Brolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration. … [L9089] Brolucizumab was granted FDA approval in October 2019.[L9089]

Pridinol

PI-0824

The goal of this therapy is to reduce the production of antibodies that cause PV blisters by acting only on the disease causing components of the immune system. … It is hoped that use of PI-0824 will reduce or potentially eliminate the need for high dose steroids and drugs that suppress the immune system.

Gastric inhibitory polypeptide

Gastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without

Lexibulin

CYT997 is an orally available vascular targeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias

NV1020

NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.